Welcome!

News Feed Item

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Trigeminal Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Trigeminal Neuralgia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Trigeminal Neuralgia 28
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Merz Pharma GmbH & Co. KgaA 29
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 29
Desitin Arzneimittel GmbH 30
Clinical Trial Overview of Desitin Arzneimittel GmbH 30
Convergence Pharmaceuticals Ltd. 31
Clinical Trial Overview of Convergence Pharmaceuticals Ltd. 31
Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Top Institutes / Government 33
Stanford University 33
Clinical Trial Overview of Stanford University 33
Thomas Jefferson University 34
Clinical Trial Overview of Thomas Jefferson University 34
University Health Network 35
Clinical Trial Overview of University Health Network 35
National Institute of Dental and Craniofacial Research 36
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 36
Shahid Sadoughi University of Medical Sciences and Health Services 37
Clinical Trial Overview of Shahid Sadoughi University of Medical Sciences and Health Services 37
FDA Office of Orphan Products Development 38
Clinical Trial Overview of FDA Office of Orphan Products Development 38
University of Malaya 39
Clinical Trial Overview of University of Malaya 39
Riken Advanced Science Institute 40
Clinical Trial Overview of Riken Advanced Science Institute 40
University College London 41
Clinical Trial Overview of University College London 41
Capital Medical University 42
Clinical Trial Overview of Capital Medical University 42
Five Key Clinical Profiles 43
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 60

List of Tables
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Trigeminal Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Trigeminal Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 29
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Desitin Arzneimittel GmbH, 2014* 30
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Convergence Pharmaceuticals Ltd., 2014* 31
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Allodynic Therapeutics, LLC, 2014* 32
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 33
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 34
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 35
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Dental and Craniofacial Research, 2014* 36
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Sadoughi University of Medical Sciences and Health Services, 2014* 37
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2014* 38
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malaya, 2014* 39
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Riken Advanced Science Institute, 2014* 40
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University College London, 2014* 41
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Capital Medical University, 2014* 42

List of Figures
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 59


Read the full report:
Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Connecting to major cloud service providers is becoming central to doing business. But your cloud provider’s performance is only as good as your connectivity solution. Massive Networks will place you in the driver's seat by exposing how you can extend your LAN from any location to include any cloud platform through an advanced high-performance connection that is secure and dedicated to your business-critical data. In his session at 21st Cloud Expo, Paul Mako, CEO & CIO of Massive Networks, wil...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...
Cloud adoption is often driven by a desire to increase efficiency, boost agility and save money. All too often, however, the reality involves unpredictable cost spikes and lack of oversight due to resource limitations. In his session at 20th Cloud Expo, Joe Kinsella, CTO and Founder of CloudHealth Technologies, tackled the question: “How do you build a fully optimized cloud?” He will examine: Why TCO is critical to achieving cloud success – and why attendees should be thinking holistically ab...
yperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let’s say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it....
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...